Key result
Daphnetin combined with doxorubicin decreased tumor size, increased body weight, and reduced systemic toxicity in esophageal cancer xenograft mice compared to doxorubicin alone.
Why the study?
Chemotherapy drugs have limitations due to side effects, and natural products may reduce these adverse effects.
Does daphnetin reduce doxorubicin-induced systemic toxicity in esophageal cancer stem cell xenograft mice?
Does daphnetin reduce doxorubicin-induced systemic toxicity in esophageal cancer stem cell xenograft mice?
Daphnetin shows potential as a chemoprotective adjuvant to reduce systemic toxicity of doxorubicin in esophageal cancer models.
Daphnetin may attenuate doxorubicin toxicity in esophageal cancer xenografts; hypothesis-generating and requires human trials before any clinical consideration.
BACKGROUND: Chemotherapy drugs commonly used for cancer therapy, but chemotherapy has limitation due to side effects. Current studies suggest natural products are reducing the side effects of chemotherapy medicines. In this study, we examined the side effects of doxorubicin (Dox) in esophageal cancer cells (CSCs) derived tumors in vivo. METHODS: Esophageal cancer cells (YMI) were treated in vitro with daphnetin (DAP) along with DOX. The MTT assay was used for estimating the cell viability and Annexin/7-AAD was used for the determination of apoptosis. Cell cycle arrest was conducted using the PI-staining method. The potential effect of DAP was evaluated by the estimation of oxidative stress such as total antioxidant capacity (TAC), malondialdehyde (MDA) and superoxide dismutase (SOD) and body weight in the xenograft mice. RESULTS: DAP can protect Dox cell toxicity by suppressing cell apoptosis of ESCC. DAP arrest the cells as S-phase. In vivo experimental study showed that Dox simultaneously with DAP decreases the tumor size along with increased body weight in the nude mice compared to Dox alone treated group mice. Dox along with the DAP exhibited less systemic toxicity and reduced oxidative stress fraction circulation. CONCLUSION: The result suggests that daphnetin may be used as an adjuvant therapy to reduce the systemic toxicity of chemotherapeutic agents, such as DOX, in stem cell treatment with ESCC cancer.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2021) studied Esophageal cancer. Daphnetin (DAP) along with doxorubicin (DOX) vs. Doxorubicin (DOX) alone was evaluated on Tumor size, body weight, and oxidative stress. Daphnetin combined with doxorubicin decreased tumor size, increased body weight, and reduced systemic toxicity in esophageal cancer xenograft mice compared to doxorubicin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: